Bracco Japan Ltd: Expanding Global Presence Bracco strengthens its global presence with the launch of Bracco Japan Ltd, enhancing diagnostic imaging capabilities across Asia.

Patents

Vuebox: Contact PRODUCT SERVICES

Bracco è Marchio Storico di Interesse Nazionale L’azienda, nata nel 1927 e oggi leader globale nella diagnostica per immagini, entra a far parte dell’esclusivo gruppo di imprese storiche che rappresentano la punta di diamante del Made in Italy.

ACR Classification of Gadopiclenol as Group II Agent Discover why ACR designated Gadopiclenol as a Group II agent and what this means for patient safety and diagnostic accuracy in MRI imaging.

Bracco Launches Iodine Recollection and Re.Viva Program Learn about Bracco’s iodine recollection pilot program and Re.Viva initiative, advancing sustainability and circular economy in diagnostic imaging.

Bracco Highlights at RSNA 2023 Join Bracco at RSNA 2023 to explore our latest innovations in medical imaging, including AI-driven tools and advanced contrast agents. 

Data Reinforcing Efficacy and Safety of Gadopiclenol in Contrast-Enhanced MRI of Certain Body Regions Published in Radiology

Data Reinforcing Efficacy and Safety of Gadopiclenol in Contrast-Enhanced MRI of Certain Body Regions Published in Radiology The results of the multicenter, international PROMISE clinical trial demonstrate that gadopiclenol provides similar lesion visualization and contrast enhancement at a gadolinium dose of 0.05 mmol/kg versus a full dose of gadobutrol (0.1 mmol/kg).

Funding the Future of Radiology¹ With an over $1.8 million investment in radiology research, Bracco Diagnostics Inc. actively supports the advancement of the field by ensuring that 34 early-career radiological investigators have access to much-needed funding.